Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison  by Bootsma, H.P.R. et al.
Long-term effects of levetiracetam and topiramate
in clinical practice: A head-to-head comparison
H.P.R. Bootsma a,*, L. Ricker a, L. Diepman a, J. Gehring a, J. Hulsman a,
D. Lambrechts a, L. Leenen a, M. Majoie a, A. Schellekens a,
M. de Krom b, A.P. Aldenkamp a,b
Seizure (2008) 17, 19—26
www.elsevier.com/locate/yseizaDepartments of Neurology, Clinical Neurophysiology, Neuropsychology and Pharmacology of
the Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands
bDepartment of Neurology, University Hospital of Maastricht, The Netherlands
Received 31 October 2006; received in revised form 19 April 2007; accepted 25 May 2007
KEYWORDS
Levetiracetam;
Topiramate;
Head-to-head
comparison;
Long-term retention;
Side effects of AEDs;
Cognitive function;
Antiepileptics
Summary
Objective: Two of the most commonly prescribed new antiepileptic drugs as add-on
therapy for patients with chronic refractory epilepsies are topiramate and levetir-
acetam. In regulatory trials, both drugs were characterized as very promising new
antiepileptic drugs. However, results from these highly controlled short-term clinical
trials cannot simply be extrapolated to everyday clinical practice, also because head-
to-head comparisons are lacking. Therefore, results from long-term open label
observational studies that compare two or more new AEDs are crucial to determine
the long-term performance of competing new antiepileptic drugs in clinical practice.
Method: We analyzed all patients referred to a tertiary epilepsy centre who had been
treated with topiramate from the introduction of the drug in spring 1993 up to a final
assessment point mid-2002 and all patients who had been treated with LEV in the
same centre from the introduction of the drug in early 2001 up to a final assessment
point end-2003 using a medical information system.
Results: Three hundred and one patients were included for levetiracetam and 429
patients for TPM. Retention rate after 1 year was 65.6% for LEV-treated patients and
51.7% for TPM-treated patients ( p = 0.0015). Similarly, retention rates for LEV were
higher at the 24-month mark: 45.8% of LEV-treated patients and 38.3% of TPM-treated
patients were still continuing treatment ( p = 0.0046). Adverse events led to drug
discontinuation in 21.9% of TPM-treated patients compared to 6.0% of LEV-treated
patients ( p < 0.001). The number of patients discontinuing treatment because of lack
of efficacy was similar for both groups. Seizure freedom rates varied between 11.6
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important AED specific adverse events leading to drug discontinuation were identi-
fied, including neurocognitive side effects from TPM and mood disorders from LEV.
Conclusion: The retention rate for LEV is significantly higher than for TPM. LEV had a
more favourable side effect profile than TPM with comparable efficacy. Patients on
TPM discontinued treatment mainly because of neurocognitive side effects. In the
treatment with LEV, the effects on mood must not be underestimated.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
The introduction of several new antiepileptic drugs
(AEDs) in the past decades may be a welcome devel-
opment for patients with refractory epilepsy.1 Two of
the most commonly prescribed ‘‘new generation’’
AEDs in the Netherlands are topiramate (TPM) and
levetiracetam (LEV). Both drugs were found to be an
effective and safe therapeutic option as adjunctive
therapy for partial seizures in adults during the reg-
ulatory well-controlled trials.2—9 Even though only
TPM has also FDA approval for primary generalized
seizures,evidence is growing that LEVmaybeauseful
broad-spectrum AED as well.10 The most frequently
reported sideeffects associatedwith theuseof LEV in
pooled analyses of the regulatory trials were somno-
lence, asthenia, headacheanddizziness.11 TPM-asso-
ciated adverse events were predominantly central
nervous system-related symptoms, including somno-
lence, dizziness and psychomotor slowing.12
However, these clinical trials were designed for
registration purposes. Regulatory studies only show
antiepileptic activity compared with placebo. It is
impossible to transfer findings derived from such
trials to everyday clinical practice13 and make com-
parisons between AEDs. In order to overcome the
shortcomings of those trials and to provide data that
can help clinicians in making treatment decisions,
other methods must be used to compare competing
new AEDs. Ideally, evidence-based treatment guide-
lines will use information from large multicenter
randomized controlled trials that compare AEDs.
These studies are, however, rarely performed.
Therefore, results from meta-analysis and long-
term open label observational studies may give
clinicians a possibility to compare the newer AEDs
despite the limitations of indirect comparisons.
Oneway tocompare the long-termperformanceof
AEDs in clinical practice is to evaluate retention
rates. Retention rate is considered to be a composite
of drug efficacy and drug safety and expresses the
willingness of patients to continue drug treatment. It
is therefore clinically themost relevant parameter of
an antiepileptic drug.14 Although TPM and LEV were
characterized as very promising AEDs in regulatory
trials, a long-term study that retrospectively
compared the retention rates of five new AEDs hasshown retention rates of 44% for TPM and 54% for
LEV15 after 2 years of follow-up. This implies that
about half of the patients will discontinue treatment
within a period of 2 years. Prospective data from
long-term open-label studies showed seizure free-
dom rates of about 10% for at least 6 months in
patients on TPM and LEV. However, withdrawal rates
due to adverse events were higher for TPM.16,17
Presently, only few data are available to show
how TPM compares to LEV in the long-term in a
single tertiary epilepsy centre. We therefore per-
formed a systematic audit of TPM and LEV in the
‘real life’ setting of our centre with the aim to
compare the long-term effects of both drugs in a
broad population, specifically retention time, effi-
cacy and tolerability in clinical practice.Method
The study was approved by the Medical Ethics Com-
mittee. All patients who had been treated with TPM
in the Epilepsy Centre Kempenhaeghe from the
introduction of the drug in spring 1993 up to a final
assessment point mid-2002 and all patients who had
been treated with LEV in the same centre from the
introduction of the drug in early 2001 up to a final
assessment point end-2003 were identified by
means of our automated medical information sys-
tem (MIS) and subsequently analyzed. Patients
whom had TPM or LEV prescribed initially elsewhere
were not included. The follow-up period for both
drugs was 24 months. A standardized data form was
developed. The data were obtained from our MIS
and individual patient medical records. Variables
that were included in the database were patient
characteristics (age, sex, weight, age at onset of
seizures, duration of epilepsy at the introduction of
drug treatment, mental retardation [defined as
IQ < 70], CT/MRI abnormalities), length of treat-
ment, efficacy, reported side effects and reasons
for discontinuation. Epilepsy and seizures were clas-
sified using the International League Against Epi-
lepsy (ILAE) classification. Treatment was evaluated
every 6 months for both drugs. Efficacy was mea-
sured using a 5-point scale: seizure remission, any
reduction in seizure frequency, no efficacy, any
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son for discontinuation of LEV and TPM was entered
into the database using a 4-point scale: no efficacy,
adverse events, both or other. Mood disorders due to
use of AEDs were classified into activating and
sedating effects, with the former leading to aggres-
sion, hyperirritability and agitation, and the latter
leading to apathy and depression.18,19 Data forms
were entered into a computerized database for
analysis. Statistical analysis was performed using
SPSS 15.0 for Windows. Retention rates were calcu-
lated by using Kaplan—Meier survival analysis,20 and
comparisons between the retention curves of TPM
and LEV were analyzed using log-rank tests. Com-
parison between both drugs in terms of seizure
remission and reason for discontinuation was ana-
lyzed using Pearson X2.Results
Three hundred and four patients were identified
using LEVand 470 patients using TPM. For LEV, threeTable 1 Patient demographics and characteristics
Total no. of patients
Age
Age range
Age distribution
Sex (F/M)
Weight (kg)
Type of epilepsy
Localization-related
Generalized (including secondarily generalized)
Undetermined
Not classified
Seizure type
Partial onset
Generalized
Not classified
Nonepileptic attacks
Age at onset of seizures
Duration of epilepsy before drug introduction (years)
No. of mentally retarded
CT abnormalities
MRI abnormalities
No. of concomitant AEDs
Most frequently used concomitant AEDs at baseline
Carbamazepine
Clobazam
Phenytoin
Lamotrigine
Oxcarbazepine
Valproic acidpatients were excluded; one patient was already
exposed to LEV on referral to our centre and of two
patients data were lacking. For TPM, 41 patients
were excluded; 37 patients were already exposed to
TPM on referral to our centre and of 4 patients data
were lacking.
Table 1 lists the main characteristics of the
patients. The mean age was 32.5  16.8 years for
LEV and 34.9  8.6 years for TPM. There was an
equal distribution with respect to gender. Age at
onset of seizures was in the 11th and 9th year,
respectively, with a duration of active epilepsy (=
years with seizures) of more than 20 years. Locali-
zation-related epilepsy was by far the most preva-
lent type of epilepsy and, consequently, partial
onset seizures the most frequently recorded type
of seizure. Children and mentally handicapped
patients were substantially and equally represented
in both study groups. The number of patients with
abnormalities on CTand MRI were similar for the two
groups. No difference could be identified in the
number of concomitant AEDs and the most fre-
quently used AEDs. Thus, both populations wereLevetiracetam Topiramate
301 429
32.5  16.8 34.9  8.6
1—75 1—73
19.9% < 18 24.5% < 18
156/145 204/225
50.5  21.6 54.0  26.6
217 (72.1%) 323 (75.3%)
54 (17.9%) 86 (20.1%)
16 (5.4%) 10 (2.3%)
14 (4.6%) 10 (2.3%)
243 (80.7%) 352 (82.1%)
138 (45.8%) 209 (48.7%)
19 (6.3%) 19 (4.4%)
28 (9.3%) 31 (7.2%)
11.7  11.7 9.7  11.1
21.3  12.9 21.1  13.4
98 (32.6%) 158 (36.8%)
17.3% 18.9%
31.9% 36.4%
2.16  0.827 2.04  0.779
39.9% 44.8%
37.6% 34.3%
15.6% 19.3%
42.5% 47.1%
16.3% 14.5%
19.3% 18.4%
22 H.P.R. Bootsma et al.
Figure 1 Comparison between the Kaplan—Meier survi-
val curves of TPM and LEV (*RR: retention rate).
Figure 3 (A) Seizure freedom rates per 6-month inter-
val; comparison between TPM and LEV. (B) Seizure remis-
sion for at least 1 year; comparison between TPM and LEV.comparable for the most important demographic
and clinical variables and represent the typical
group of refractory patients referred to a tertiary
epilepsy centre.
Retention rates for TPM and LEV are illustrated
with Kaplan—Meier survival curves in Fig. 1. Reten-
tion rate after 1 year was 65.6% for LEV-treated
patients and 51.7% for TPM-treated patients
( p = 0.0015). Similarly, retention rates for LEV
were significantly higher at the 24-month mark:
45.8% of LEV-treated patients and 38.3% of TPM-
treated patients were still continuing treatment
( p = 0.0046). However, at 6 months follow-up,
there was no significant difference between the
two profiles ( p = 0.1088). For both drugs, it is shown
that the largest percentage of discontinuations
occurred in the first period of treatment with a
rapid drop of retention rates until about 400 days,
after which a plateau seems to be reached.
The main reasons for drug discontinuation
are shown in Fig. 2. Adverse events led to drug
discontinuation in 21.9% of TPM-treated patients
compared to 6.0% of LEV-treated patients
( p < 0.001). The number of patients discontinuing
treatment because of lack of efficacy or the com-
bination of lack of efficacy and adverse events was
similar for both groups.Figure 2 Reason for discontinuation; comparison
between TPM and LEV.For LEV, adverse events were the most important
reason for drug discontinuation during the first 3
months. Thereafter, lack of efficacy played the most
important role in drug discontinuation. For TPM,
however, tolerability issues lasted much longer
and were the main reason for drug discontinuation
in the first 18 months.
Seizure freedom rates per 6-month interval are
illustrated in Fig. 3A. Seizure freedom rates varied
between 11.6 and 20.0% for TPM and between 11.1
and 14.3% for LEV. No statistically significant dif-
ferences between TPM and LEV could be identified
at 6 months ( p = 0.468), 12 months ( p = 0.653)
and 18 months ( p = 0.244). Fig. 3B shows the
number of patients completely seizure-free for
at least 1 year. Seizure remission rates for the
intervals T0—T12 and T0—T18 were higher for LEV,
although not statistically significant ( p = 0.618
and 0.416, respectively). For the interval T6—
T18, remission rates were similar for both drugs
( p = 0.929).
Table 2 shows the most frequently reported
adverse events per assessment point. The most
prevalent adverse events for LEV were activating
mood disorders and tiredness. Some patients experi-
enced a positive effect on their behaviour due to
LEV use. For TPM, mental slowing and dysphasia
were the most important side effects at each assess-
ment point, except for the 24-month assessment
point.
Long-term effects of levetiracetam and topiramate in clinical practice 23
Table 2 Most frequently reported side effectsa
Levetiracetam Topiramate
6 Months Mood disorders "b (8.1%) Mental slowing (13.8%)
Tiredness (7.4%) Dysphasiac (6.6%)
Positive behaviourd (7.4%) Weight loss (5.2%)
12 Months Mood disorders " (5.2%) Mental slowing (13.6%)
Dysphasia (5.7%)
18 Months Mood disorders " (10.6%) Mental slowing (8.1%)
Tiredness (6.4%) Dysphasia (6.5%)
Mood disorders " (5.7%)
24 Months (Number of patients too small to provide meaningful data) Urogenital complaintse
(5.6%)
a Only side effects that occurred in >5% of the patients are reported in the table.
b Mood disorders ": agitation, aggression, hyperirritability.
c Dysphasia: word-finding difficulties.
d Positive behaviour: being in a better condition; taking more initiatives; being more calm, active, cheerful, etc.
e Urogenital complaints: impotence, amenorrhea, micturation problems, etc.The most frequently reported side effects in
patients who discontinued treatment are listed in
Table 3. For LEV, more than a quarter of patients
(26.9%) reported mood disorders at the time of
discontinuation, with an equal distribution of acti-
vating and sedating mood disorders. Tiredness and
sleepiness were also important side effects at time
of discontinuation (13.8 and 8.5%, respectively). In
patients on TPM, mood disorders were also fre-
quently reported (18.9%), although sedating mood
disorders played a less important role. Side effects
other than mood disorders that most often led to
discontinuation of TPM treatment were mental
slowing (27.8%) and dysphasia (15.0%). Other sideTable 3 Reported side effects in patients who discon-
tinued drug treatmenta
Levetiracetam Topiramate
Mood disorders "b
(13.8%)
Mental slowing (27.8%)
Tiredness (13.8%) Dysphasiac (15.0%)
Mood disorders #d
(13.1%)
Mood disorders " (13.2%)
Sleepiness (8.5%) Gastrointestinal
complaints (10.6%)
Paresthesia (7.5%)
Appetite loss (7.0%)
Skin complaints (6.6%)
Weight loss (6.2%)
Mood disorders # (5.7%)
Headache (5.7%)
Dizziness (5.3%)
a Only side effects that occurred in >5% of the patients are
reported in the table.
b Mood disorders ": agitation, aggression, hyperirritability.
c Dysphasia: word-finding difficulties.
d Mood disorders #: depression, apathy.effects that were frequently reported were gastro-
intestinal complaints, paresthesia, appetite loss,
skin complaints, weight loss, headache and dizzi-
ness.
Table 4 shows seizure reduction in patients who
discontinued treatment. One patient (0.8%) was
seizure-free when discontinuing LEV compared to
four patients (1.8%) who were seizure-free on TPM.
In spite of the anticonvulsive effect of drug treat-
ment, twice as many patients discontinued TPM.
More patients on LEV experienced no efficacy or
even a higher seizure frequency compared to
patients on TPM.Discussion
While many studies have been done on each indivi-
dual new AED as add-on therapy, few compare these
new AEDs with each other. Especially large multi-
center randomized controlled trials that compare
two or more AEDs are rare but crucial in clinical
decision-making. Pharmaceutical companies have
serious reservations funding these trials, unless
there was confidence that the sponsor’s drug wasTable 4 Seizure reduction in patients who discontin-
ued drug treatment; follow-up period 24 months
Levetiracetam Topiramate
Seizure-free 1 (0.8%) 4 (1.8%)
Lower seizure
frequency
6 (4.7%) 19 (8.6%)
No efficacy 69 (53.5%) 75 (33.8%)
Higher seizure
frequency
30 (23.3%) 66 (29.7%)
Not reported 23 (17.7%) 58 (26.1%)
24 H.P.R. Bootsma et al.very likely to prove superior to the comparator. In
the absence of such comparative clinical trials,
indirect comparisons have been made using meta-
analyses of controlled trials and reviews of long-
term open-label studies to adequately evaluate the
benefits and risks of treatment of epilepsy. The
relevance of findings derived from such studies to
everyday clinical practice is limited by several fac-
tors, especially by the indirect character of the
comparisons due to differences between studies
in study design, study population and placebo-
effect.21,22 However, both methods have gone some
way to compare new AEDs and provide some evi-
dence of the relative efficacy and tolerability of
competing new AEDs. Moreover, observational stu-
dies are known to be useful adjuncts to controlled
trials to see whether the demonstrated efficacy and
safety translates into effective and safe treatment
in routine clinical practice.23
Our study directly compared the use of TPM with
LEV, presently two of the most commonly prescribed
new AEDs in chronic epilepsy. The study population
consisted of patients with chronic refractory epi-
lepsy referred to a single tertiary epilepsy centre.
The added value of this study is due to the head-to-
head comparison made between TPM and LEV in a
single epilepsy centre, the large number of patients
included (n = 301 for LEV; n = 429 for TPM), the long
period of evaluation (24 months) and the low risk of
selection bias by the inclusion of all patients who
were treated with LEV or TPM in a certain period.
This is illustrated by the characteristics of our study
population, specifically by a wide age range and a
large number of children and mentally retarded.
The patients on LEV did not differ on any of the
clinical or demographical variables when compared
to the patients on TPM, which allows us to compare
TPM to LEV and to assume that differences in out-
come are drug-related.
For clinical decision-making, retention rate is a
good indicator of the long-term performance of a
new AED.24 It measures all possible reasons for drug
discontinuation, including ineffectiveness and intol-
erability. In addition, it expresses the consent of an
individual patient to continue drug treatment,
sometimes even with side effects. Therefore, the
main purpose of our study was to determine long-
term retention rates for TPM and LEV. Retention
rates were 65.6 and 45.8% for LEV and 51.7 and
38.3% for TPM after 1 and 2 years, respectively.
Other studies showed similar 1-year retention rates
ranging from 60 to 75% for LEV and 40 to 60% for
TPM.21 The statistically significant difference in 1-
and 2-year retention rates is probably the conse-
quence of a more unfavourable safety profile of
TPM. At 6 months follow-up, no significant differ-ence was seen between both drugs. This implies that
it is hard to show differences in discontinuation
rates between TPM and LEV in short-term trials,
even when a large number of patients are investi-
gated.
Several findings with regard to retention rates
were noteworthy in our study. Retention rates could
have been influenced by the sequence in which both
drugs were marketed. Patients on TPM could have
been withdrawn from treatment because of the
availability of the new AED LEV. On the other hand,
LEV could have been tested in a more refractory
population, since LEV was introduced onto the mar-
ket years after TPM.
Interestingly, the difference between continua-
tion rates for both drugs became smaller after 1-
year follow-up. We do not know whether there will
still be a significant difference after many years.
This is an important issue, since patients with
refractory epilepsy often need lifetime treatment.
One study that compared the long-term retention
rates of new AEDs in a residential community of
adults with chronic epilepsy showed a similar dif-
ference in 2-year retention rates between TPM and
LEV compared with our study. However, this differ-
ence almost disappeared after 5 years.25
Elsewhere, our study group showed 1-, 2-, 3- and
4-year retention rates for TPM to be 53, 45, 38 and
30%, respectively.26 These data suggest that surviv-
ing the early stage of TPM introduction is a good
indicator of long-term retention, with most with-
drawals occurring in the first year. With LEV use, we
have shown a similar pattern with most patients also
discontinuing treatment in the first year, after which
the number of withdrawals more or less remained
steady at a lower rate.
Drugs that were mostly encountered as concomi-
tant therapy were carbamazepine, clobazam, phe-
nytoin, lamotrigine, oxcarbazepine and valproic
acid. At baseline, no differences in the most fre-
quently used concomitant AEDs between TPM and
LEV could be identified. Since both drugs were
prescribed as adjunctive treatment to an existing
regime, we assume that similar baseline concomi-
tant AEDs characteristics prolonged during follow-
up. However, if not so, differences in concomitant
AEDs between TPM and LEV could have influenced
the efficacy and safety profile of each individual
drug.
In our study, percentages of patients discontinu-
ing drug treatment because of lack of efficacy were
similar for both study groups, suggesting TPM and
LEV to be equally effective. A meta-analysis of well-
controlled trials showed comparable efficacy
between both drugs using a responder rate of
50% reduction in seizure frequency.22 Zaccara
Long-term effects of levetiracetam and topiramate in clinical practice 25et al. who reviewed long-term open-label studies
used seizure-free outcomes as ameasure of efficacy.
LEV turned out to be the most effective agent,
followed by TPM. However, analysis limited to pro-
spective studies showed that TPM had the highest
percentage of seizure-free patients.21
Main objective in the treatment of epilepsy is
control of seizures. The achievement of seizure
freedom is an essential outcome measure, because
it has the greatest impact on quality of life27 and it is
the efficacy measure that is subject to the least
subjectivity. Responder rates, defined as a percen-
tage reduction in seizure frequency, do not take into
account the duration and severity of seizures. In
addition, data reflecting the number of seizures are
often unreliable, especially in retrospective stu-
dies. Therefore, our study only presented data
regarding seizure freedom rates, although seizure
remission is not a realistic goal for every patient
with refractory epilepsy.
Comparable percentages of patients on TPM and
LEV achieved seizure freedom for 6 months in our
study. Between 11.6 and 20.0% of patients on TPM
were seizure-free compared to 11.1—14.3% of
patients on LEV. These figures compare well to those
presented in literature, although seizure freedom
rates vary a lot among different studies. Four to
twenty-three percent of patients were reported to
be free of seizures on TPM compared to 9.8—26.0%
of patients on LEV, dependent on study design and
study population.21
The proportion of patients with complete seizure
control for longer periods of time provides even
more clinically meaningful data for predicting the
long-term efficacy of an AED.23 Therefore, we have
also investigated long-term seizure remission. From
baseline, more patients on LEV achieved seizure
remission for at least 1 year, although this difference
was not statistically significant. Possibly, this differ-
ence is due to a rapid onset of action of LEV.28
However, if the titration period is not taken into
account (i.e. in the interval T6—T18), prolonged
seizure remission was achieved in more than 12%
of patients in both the TPM and LEV study group,
which is a good result in this highly refractory
population.
As a marker of tolerability, we used the percen-
tage of patients withdrawing drug treatment
because of adverse events. Our study shows that
significantly more patients discontinued TPM treat-
ment because of adverse events than patients on
LEV. This is also illustrated by the time period in
which adverse events were the main reason for drug
discontinuation; only in the first 3 months side
effects played a more important role than lack of
efficacy with LEV use compared to the first 18months in patients on TPM. Titration rates are unli-
kely to be responsible for the high incidence of
adverse events in patients on TPM.26 Thus, TPM
was by far the least well-tolerated drug. This finding
is supported by other studies reporting that TPM has
a higher rate of adverse events leading to with-
drawal than LEV16,21,22 and by our data showing that
twice as many patients on TPM discontinued treat-
ment despite the beneficial effects on seizure fre-
quency compared to LEV. In these patients, the
adverse events can therefore be considered very
serious.
Side effect profiles of TPM and LEV are different;
neurocognitive complaints are very common in TPM
treatment and frequently led to drug withdrawal,
while the impact of LEV on cognitive function is only
very mild. One study showed that the neurocogni-
tive effects of TPM occurred already at an early
stage, while the remaining patients do not have such
problems.29 However, in our study, the percentage
of patients with neurocognitive side effects due to
TPM use remained high. Mood disorders were
reported in both drugs, but is was the most common
reason for discontinuation in patients on LEV. This
contributes to clinical reports that behavioural
adverse events are more common in LEV than in
TPM30 and that patients taking LEVexperience more
behavioural symptoms than reported in RCTs.31 In
our study, mood disorders in patients on LEV
emerged from the beginning. It is therefore not
clear why RCTs only reported somnolence, asthenia,
headache and dizziness as major side effects. An
explanation could be that patients with learning
disabilities are more prone to behavioural side
effects.31 This population is often excluded in
well-controlled randomized clinical trials and some
large scale open-label multicenter trials with
reports of behavioural adverse events only occurring
at a low rate.32,33
In conclusion, the retention rate for LEV is sig-
nificantly higher than for TPM. LEV had a more
favourable side effect profile than TPM with com-
parable efficacy. Patients on TPM discontinued
treatment mainly because of neurocognitive side
effects. In the treatment with LEV, the effects on
mood must not be underestimated.References
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